New hope for Hard-to-Treat brain cancer: targeted radiation trial launches

NCT ID NCT06132737

Recruiting now Disease control Sponsor: Pentixapharm AG Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug called [90Y]Y-PentixaTher for people with central nervous system (CNS) lymphoma that has come back or not responded to standard treatments. The drug delivers radiation directly to cancer cells. About 15 participants will receive one intravenous dose, and researchers will monitor safety, how the drug spreads in the body, and whether it shrinks tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CNS LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary central nervous system lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CNS LYMPHOMA

Contacts and locations

Locations

University Hospital Essen
RECRUITING

Essen, Germany
University Hospital Rechts der Isar
WITHDRAWN

Munich, Bavaria, 81675, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.